- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05691218
Early High-flow Oxygen Therapy With nebuLized Beta-2-agonist Using a Vibrating Mesh for the Management of Moderate to Severe Asthma Exacerbation in the Emergency Department (EOLE)
Acute exacerbation of asthma represents an acute or sub-acute worsening in symptoms and lung function in patients with asthma. It is characterized by a progressive increase in symptoms of shortness of breath, cough, wheezing, or chest tightness. It is a common diagnosis in patients admitted in an Emergency Department for dyspnoea. Near 10 to 15% of respiratory symptoms in an ED are related to acute exacerbation of asthma.
Treatment of acute exacerbation of asthma associates nebulized beta-2 agonist adrenergic with or without ipratropium bromide, oral corticosteroids and controlled oxygen therapy to maintain SpO2 between 93 and 95%. Treatment in the ED did not vary during last years, including for patients with a lack of efficacy after first line treatment, and exacerbation are always associated with a hospitalisation in 40% of adult patients and with mortality in 1% of hospitalized patients.
Vibrating mesh nebulizers are devices using vibration to push drug through the mesh, resulting in the drug nebulization. Vibrating mesh nebulizers have been associated with better pulmonary drug delivery than jet-nebulizers, provide faster improvement in peak expiratory flow and have been associated in retrospective studies with patient prognosis, particularly in terms of throughput time and need for hospitalisation. However, no studies have prospectively compared nebulisation with a vibrating membrane device with standard nebulisation in patients with asthma exacerbation on clinically relevant criteria. Nebulisation with a vibrating membrane device may potentiate the clinical efficacy of short-acting bronchodilators, result in faster and more effective clinical improvement, and be associated with improved short- and medium-term patient outcomes.
High-flow nasal cannula heated, and humidified oxygen (HNFO) is a ventilatory support which is commonly used for the management of acute respiratory failure for acute respiratory failure in intensive care units and in emergency departments. HFNO delivers high fraction of inspired oxygen (FiO2), generates a low level of positive pressure and provides washout of dead space in the upper airways, thereby improving mechanical pulmonary properties and unloading inspiratory muscles during ARF. Consequently, HFNO is associated with a decrease in the work of breathing. During asthma exacerbation, HFNO was associated with an improvement in the dyspnea level and in the respiratory rate compared with conventional oxygen therapy. However, HFNO has never been assessed in association with nebulized beta-2 adrenergic agonist.
To resume, beta-2 adrenergic agonist nebulization with a vibrating mesh nebulizer seems effective, especially compared to standard jet nebulization. In addition, HFNO is a technique that appears to be suitable for the pathophysiological conditions of chronic reversible respiratory failure, and can be used during exacerbations of asthmatic disease. The high flow rate of gas makes it possible to control the FiO2 in order to avoid hyperoxia, to generate a PEEP effect, to reduce the patient's work of breathing and the respiratory resistance, and to avoid the re-inhalation of CO2 by a dead space wash-out.
In the EOLE study, the investigators propose to compare three therapeutic management strategies. One standard strategy (nebulisation with a jet-nebulizer), and two experimental strategies (nebulisation with a vibrating mesh device, and nebulisation with a vibrating mesh device in association with HFNO).
The investigators hypothesise that bronchodilator nebulization with a vibrating mesh nebulizer is more effective than jet-nebulizers for the management of patients admitted for asthma exacerbation and non-responders or with lack to efficacy to initial treatment. Furthermore, the investigators also hypothesise that the addition of the physiological effects of HFNO may enhance the efficacy of the treatment.
The therapeutic effects of nebulisation with a vibrating membrane device alone or with the addition of the physiological effects of HFNO could constitute a new approach to the management of asthma patients, particularly in patients who are insufficiently responsive or non-respondent to initial treatment.
Study Overview
Status
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sabrina SEGUIN, CRA
- Phone Number: +33 0549443229
- Email: sabrina.seguin@chu-poitiers.fr
Study Contact Backup
- Name: Nicolas MARJANOVIC, MD PHD
- Phone Number: +33 0549441873
- Email: nicolas.marjanovic@chu-poitiers.fr
Study Locations
-
-
-
Poitiers, France, 86021
- Recruiting
- University Hospital of Poitiers
-
Contact:
- Sabrina SEGUIN, CRA
- Phone Number: +33 0549443229
- Email: sabrina.seguin@chu-poitiers.fr
-
Contact:
- Nicolas MARJANOVIC, MD PHD
- Phone Number: +33 0549441873
- Email: nicolas.marjanovic@chu-poitiers.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age equal or over 18 years
- admitted in an Emergency Department with a clinical suspicion of acute exacerbation of asthma according to the Global Initiative for Asthma (GINA) criteria.
with at least one of the following criteria 60mn after a first treatment by beta-2 agonist adrenergic nebulization with 3 x 5 mg of terbutaline:
- Respiratory rate over 22 breaths/min
- Peak flow < 50% of predictive normal value
- SpO2 < 95% in room air
- Signs of severe asthma exacerbation (at least one criteria):
Talks in word, Agitation, Sits hunched forwards, Accessory muscles in use
- Free subject, without guardianship or curatorship or subordination
- Patients benefiting from a Social Security scheme or benefiting from it through a third party
- Informed consent signed by the patient after clear and honest information about the study
Exclusion Criteria:
- Acute exacerbation of asthma during the last 30 days
- Clinical suspicion of acute exacerbation of asthma due to anaphylaxis, pneumothorax, pneumomediastinum, pneumonia or atelectasis.
- At least ONE of the following serious signs: drowsiness, confusion, auscultatory silence
- Clinical suspicion of another pathology that could explain the respiratory failure such as heart failure, laryngeal obstruction, pulmonary embolism, etc
- Patients with neurological (Glasgow < 13) or hemodynamical failure (Mean Arterial Pressure < 65 mmHg)
- contraindication to treatment with a beta-2-adrenergic agonist
- History of hypersensitivity (allergy) to terbutaline or any of the constituents
- Contraindication to OHD
- Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, people assessed GIR1 or GIR 2 (AGGIR grid), adults under legal protection
- Pregnant or breastfeeding women, Women at age to procreate and not using effective contraception
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control - Standard Nebulization
|
Beta-2 adrenergic agonist administred by standrad nebulization
|
Experimental: A-Vibrating mesh Nebulization
|
Beta-2 adrenergic agonist nebulisation using a vibrating mesh nebuliser device (Aerogen, Galway, Ireland).
Nebulisation will take place under medical air at 6L/min or medical O2 at 6L/min depending on the patient's needs and for a SpO2 target between 94-96%
|
Experimental: B-Vibrating mesh Nebulization and High-flow nasal cannula heated and humidified oxygen
|
High-flow nasal cannula heated and humidified oxygen (HFNO) and nebulisation of beta-adrenergic agonist using a vibrating mesh device. HFNO will be administered using an Airvo2 device and beta-2 adrenergic agonist nebulisation enabled by the use of a dedicated heated humidifier and an adaptable vibrating mesh nebuliser device |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of responding patients one hour after inclusion
Time Frame: 1 hour
|
A responding patient is defined by a patient responding to all the following criteria :
|
1 hour
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nicolas MARJANOVIC, MD PHD, CHU Poitiers
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EOLE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Moderate Asthma Exacerbation
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Khyber Teaching HospitalRecruitingChildhood Asthma With Acute ExacerbationPakistan
-
University of Massachusetts, WorcesterWithdrawn
-
KoBioLabsNovotech (Australia) Pty LimitedCompletedModerate to Severe AsthmaAustralia
-
Tufts Medical CenterCompleted
-
Hannover Medical SchoolCompletedCommunity-acquired Pneumonia | Antimicrobial Stewardship | Exacerbation Copd | Lower Respiratory Tract and Lung Infections | Exacerbation of Allergic AsthmaGermany
-
Societa Italiana di PneumologiaSocietà Italiana di Allergologia, Asma e Immunologia ClinicaRecruiting
-
Lawson Health Research InstituteCompletedAsthma ExacerbationCanada
-
Brian JacobsSiemens MedicalCompletedAsthma ExacerbationUnited States
Clinical Trials on Standard Nebulization
-
Phoenix Children's HospitalUnknown
-
Postgraduate Institute of Medical Education and...Recruiting
-
Cliniques universitaires Saint-Luc- Université...CompletedTracheostomized PatientsBelgium
-
National University Health System, SingaporeTerminatedChronic Obstructive Pulmonary Disease (COPD) | Type 2 Respiratory FailureSingapore
-
Aerami TherapeuticsCompletedPulmonary Arterial HypertensionAustralia
-
Thammasat UniversityNot yet recruitingAsthma Exacerbation | Emergency Department | Nebulization
-
University of North Carolina, Chapel HillCystic Fibrosis FoundationRecruiting
-
Krystal Biotech, Inc.Recruiting
-
Krystal Biotech, Inc.Novotech (Australia) Pty LimitedWithdrawn
-
Krystal Biotech, Inc.RecruitingAlpha 1-Antitrypsin DeficiencyUnited States